Lv12
40 积分 2025-07-15 加入
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
14小时前
待确认
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
14小时前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
14小时前
已完结
Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data
1天前
已完结
Improved survival with SBRT plus PD-1/PD-L1 inhibitors in lung metastases patients: A propensity score-matched study
5天前
已完结
68 Ga-NODAGA-SNA006 PET/CT Imaging of Tumor CD8 + T-Cell Infiltration Predicts Immunotherapy Response in Lung Cancer
10天前
已关闭
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review
11天前
已完结
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer
15天前
已完结
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis
15天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
16天前
已完结
皖公网安备34019202002308